Anixa Biosciences (ANIX): CEO on Breast Cancer Vaccine, Phase 2 Catalyst & Ovarian Cancer CAR-T Data
Apr. 27, 2026
Anixa Biosciences (Nasdaq: ANIX) is advancing a clinical-stage oncology pipeline focused on cancer vaccines and CAR-T therapy, led by its breast cancer vaccine program developed with Cleveland Clinic and supported by U.S. Department of Defense funding.
In our exclusive interview, Dr. Amit Kumar, Chairman & CEO of Anixa Biosciences, discusses the company’s breast cancer vaccine targeting alpha-lactalbumin, its completed Phase 1 study, the path toward Phase 2, and the long-term vision of potentially preventing breast cancer before it starts. Dr. Kumar also highlights Anixa’s ovarian cancer CAR-T program, where early clinical data has shown extended survival in certain heavily pretreated patients.
